EMA Clarifies HPV Vaccine Safety Profile

July 13, 2015
Pharmaceutical Technology Editors

The European Medicines Agency reviews the safety of human papillomavirus vaccines.

 

The European Medicines Agency is performing a review of human papillomavirus (HPV) vaccines in order to clarify the vaccines’ safety profiles. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC), which monitors the safety of vaccines, will review available data on complex regional pain syndrome (CRPS) and postural orthostatic tachycardia syndrome (POTS).

The purpose of the review is to determine if cases reported of the two syndromes is greater or lesser in those who have received the HPV vaccine. PRAC will review scientific research to determine if there is a causal link between the vaccine and CRPS and POTS frequency.

According to EMA, HPV vaccines have been used worldwide in approximately 72 million people for the prevention of cancer caused by HPV. EMA states that they are “not questioning that the benefits of HPV vaccines outweigh their risks.”

Source: EMA